

Brand Institute is proud to have partnered on the brand name development for AveXis' Zolgensma®

The first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)



zolgensma®
 (onasemnogene
 abeparvovec-xioi)
 suspension for intravenous infusion



Contact your local Brand Institute Office to discuss our experience and capabilities in developing gene therapy nonproprietary and brand names

Corporate Headquarters

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL +41 78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49 1726-574-189	LONDON +44 7896-875-113	LOS ANGELES (310) 830-6111	NEW YORK (212) 557-2100	OTTAWA (613) 482-1333
RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SAN JUAN (787) 968-3007	SÃO PAULO +55 11 945-364-083	SEATTLE (206) 204-5111	SEOUL +82 10-8000-4842	TOKYO +81 80-6688-6653	TORONTO (416) 622-5777